Sagimet Biosciences Inc. Series A Company Profile
NASDAQ: SGMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Sagimet Biosciences Series A at a glance
Sagimet Biosciences Inc. Series A (NASDAQ: SGMT) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in San Mateo, CA. Sagimet Biosciences Series A is led by Mr. David A. Happel and employs about 16 people. The company's shares have traded publicly since 2023.
At a market capitalization of $648.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001400118, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Sagimet Biosciences Series A do?
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Business description based on the company's public filings.
Company information
- Legal name
- Sagimet Biosciences Inc. Series A
- Ticker
- NASDAQ: SGMT
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. David A. Happel
- Employees
- 16
- Headquarters
- 155 Bovet Road, San Mateo, CA, United States
- Phone
- 650 561 8600
- Website
- sagimet.com
- IPO year
- 2023
- Market cap
- $648.02M
- SEC CIK
- 0001400118
- Latest annual report
- 10-K · Mar 11, 2026
Companies similar to Sagimet Biosciences Series A
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KURAKura Oncology Inc. | 6.91 | -5.99% | $634.88M | vs SGMT |
| NVCTNuvectis Pharma Inc. | 19.39 | -2.27% | $666.80M | vs SGMT |
| APMDApnimed Inc. | 16.09 | -6.70% | $669.84M | vs SGMT |
| JANXJanux Therapeutics Inc. | 10.08 | -2.04% | $616.73M | vs SGMT |
| ABUSArbutus Biopharma Corporation | 4.02 | -1.23% | $616.24M | vs SGMT |
| OLMAOlema Oncology Inc. | 7.02 | -1.82% | $615.00M | vs SGMT |
| LXRXLexicon Pharmaceuticals Inc. | 1.53 | -8.38% | $681.21M | vs SGMT |
| ANNXAnnexon Inc. | 3.10 | -9.09% | $591.37M | vs SGMT |